A promising new drug for treating osteoporosis in postmenopausal women at high risk of bone fractures is expected to be available as soon as next week.
The U.S. Food and Drug Administration (FDA) approved the new medication romosozumab (brand name Evenity), from the drugmaker Amgen, which appears to dramatically boost bone density. Amgen reports that it will also make price information available next week.
Doctors are optimistic that the drug will greatly reduce fracture risk, beyond what the dozen existing medications have been able to do, for patients with more severe osteoporosis.
“It seems like there are a lot of medications for osteoporosis, but actually the choices are few,” notes Robert A. Adler, M.D., who was a member of the FDA drug review panel for romosozumab and who serves as chief of endocrinology and metabolism at the McGuire Veterans Affairs Medical Center, in Richmond, Va.
The majority of current medications — including Fosamax and Boniva — are bisphosphonates that slow or prevent the loss of bone density but don’t rebuild bone. This is also the class of drugs spurned by some patients after reports of rare but frightening side effects like femur fractures and a type of bone deterioration (osteonecrosis) in the jaw.
But the new medicine, which belongs to a class of osteoporosis drugs known as anabolics (there are two others of this type available now), is a clear standout, says Adler. “The rise in bone density after romosozumab is greater than after any other osteoporosis medication.”
What’s more, “small changes in bone density lead to large decreases in fracture risk,” he adds.
And bone density changes with this drug appear pretty darn big. In two clinical trials involving more than 11,000 women with postmenopausal osteoporosis, romosozumab appeared to lower the risk of spinal fracture by 73 percent compared with a placebo.
For expert tips to help feel your best, get AARP’s monthly Health newsletter.